CLINICAL TRIALS PROFILE FOR SAPACITABINE
✉ Email this page to a colleague
Clinical Trials for Sapacitabine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00380653 ↗ | Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes | Completed | Cyclacel Pharmaceuticals, Inc. | Phase 1 | The goal of this study to find the highest tolerable dose of sapacitabine that can be given to patients with advanced leukemias or myelodysplastic syndromes. |
NCT00476554 ↗ | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma | Terminated | Cyclacel Pharmaceuticals, Inc. | Phase 2 | This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2 systemic therapies. |
NCT00590187 ↗ | Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients | Completed | Cyclacel Pharmaceuticals, Inc. | Phase 2 | The main objective of this study is to learn which sapacitabine treatment is more likely to keep the cancer in check for at least one year in AML patients who are at least 70 years of age or older and in MDS patients who are at least 60 years of age. |
NCT00885963 ↗ | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer | Terminated | Cyclacel Pharmaceuticals, Inc. | Phase 2 | This is an open label, single arm, phase II study to evaluate the safety and efficacy of oral sapacitabine administered twice daily for 5 consecutive days every week for 2 weeks followed by 7-day rest in patients who have had one prior chemotherapy regimen for advanced Non-Small Cell Lung Cancer (NSCLC). |
NCT00999401 ↗ | A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors | Unknown status | Cyclacel Pharmaceuticals, Inc. | Phase 1 | The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Sapacitabine
Condition Name
Clinical Trial Locations for Sapacitabine
Trials by Country
Clinical Trial Progress for Sapacitabine
Clinical Trial Phase
Clinical Trial Sponsors for Sapacitabine
Sponsor Name